Latest Juvenile Diabetes Research Foundation Stories
The idea is to teach the immune system of children at high risk for type 1 diabetes not to attack the insulin-producing cells of the pancreas.
"KidCare Kit" offers quick-reference materials and multimedia tools to guide families through the first 30 days following a child's diagnosis BRIDGEWATER, N.J., Feb. 3 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S.
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein,
Researchers at the University of Pittsburgh School of Medicine, funded by JDRF, have discovered that adult beta cells have the ability to replicate with the help of a protein known as cdk6.
Metabolic disturbances indicate progress of the disease even years in advance.
Doctors have tricked mouse immune systems into thinking cells from a donor pancreas are theirs, bringing hope to diabetes patients, U.S.
NEW YORK, Nov. 14 /PRNewswire/ -- Data from a new global survey released on World Diabetes Day finds that many teens and young adults with type 1 diabetes are optimistic about their future, but report a lack of support from school staff.
Bayhill Therapeutics, a biopharmaceutical company, and the Juvenile Diabetes Research Foundation have announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes Type 1 diabetes.
TARRYTOWN, N.Y., Oct. 30 /PRNewswire/ -- To kick off Diabetes Awareness Month, Bayer Diabetes Care announced that four people with diabetes have won the opportunity to meet teen pop sensation Nick Jonas of the Jonas Brothers after entering the national "Walk In Nick's Shoes" (W.I.N.S.) sweepstakes.
Bayhill Therapeutics, Inc., a leading developer of therapies for autoimmune diseases, and the Juvenile Diabetes Research Foundation, the world's leading charitable funder of type 1 diabetes research, today announced a partnership to support Bayhill's ongoing Phase I/II human clinical trial of BHT-3021, a DNA vaccine to reverse the immune response that causes type 1 diabetes.
- An interdisciplinary study of social injustice.